Johnson & Johnson says it won't enforce secondary patents on tuberculosis med Sirturo

After allowing generic competition and slashing the price of its multidrug-resistant tuberculosis (MDR-TB) med Sirturo (bedaquiline) in low- and middle-income countries, Johnson & Johnson has taken its access efforts a step further by committing to not enforce secondary patents on the treatment in 134 countries.